# 總部位於聖荷西的 Rani 在盤前交易中股價翻倍。

*biotech · news · 2025-10-17 · Reuters*

## Key points

- Rani 將從中外製藥獲得 1,000 萬美元前期付款及最高 1.75 億美元的里程碑款項。
- 中外製藥可依類似財務條款授權 Rani 最多五個額外計畫。
- 首個授權計畫針對罕見疾病，採用口服給藥平台。
- 交易所得預計將資助 Rani 營運至 2028 年。

Shares of San Jose-based Rani more than doubled in premarket trading. Sign up here. Under the deal, Rani will receive a $10 million upfront payment, up to $75 million in technology transfer and development milestones, as well as up to $100 million in sales milestones and single-digit royalties for the first licensed program, which targets a rare disease. Tokyo-based Chugai has the option to license up to five additional under similar terms. This partnership combines Rani's oral drug delivery platform and Chugai's expertise in complex antibodies in global markets, said Talat Imran, chief executive officer of drug developer Rani. He added in many instances, oral treatments for various diseases are limited, causing patients to rely on injections, which can be burdensome and impact adherence. Rani also announced a $60.3 million private placement led by Samsara BioCapital, with participation from new and existing investors. The company said the private placement proceeds, initial upfront payment and the expected technology transfer milestones of $18 million from Chugai are expected to fund its operations into 2028. Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore

**Companies:** Rani, Chugai
**Countries:** United States, Japan

[Read the full story on Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/rani-therapeutics-signs-up-109-billion-licensing-deal-with-japans-chugai-pharma-2025-10-17/)

---

Canonical: https://newsio.io/zh-TW/n/e5170a92-4bc6-44a1-bca9-fdedccc8d926/rani-rani-1000
Summarized by Newsio from Reuters. https://newsio.io/how-it-works